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Decreased Oxidative Stress in Patients
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OBJECTIVES In a substudy to a recently reported investigation that demonstrated the benefit of immuno-
globulin adsorption (immunoadsorption) for patients with idiopathic dilated cardiomyopathy
(IDC), we tested whether this benefit is associated with a reduction of oxidative stress.
BACKGROUND The progression of cardiomyopathy is believed to be related to the increase of oxidative stress.
Therefore, reduction of oxidative stress could be one of the effects of immunoadsorption for
improvement of cardiac performance and clinical status.
METHODS Plasma markers for oxidative stress—thiobarbituric acid-reactive substances (TBARS), lipid
peroxides (LPO), anti-oxidized low-density lipoprotein-autoantibodies (anti-oxLDL-AB),
thiol groups and vitamin E—were compared in 31 patients, of whom 16 underwent
immunoadsorption and 15 received conventional treatment (controls). All patients received a
daily supplement of vitamins, minerals and trace elements.
RESULTS After one year, TBARS (p 5 0.026), LPO (p 5 0.026) and anti-oxLDL-AB (p 5 0.044)
were decreased in the immunoadsorption group but not in the controls. Thiols were
unchanged in the immunoadsorption group but were decreased in the controls (p 5 0.001).
Vitamin E accumulated in both groups (immunoadsorption: p 5 0.001; controls: p 5 0.031)
with a trend for stronger accumulation after immunoadsorption (p 5 0.09). Prior to the study,
the anti-oxLDL-AB to left ventricular ejection fraction (LVEF) (p 5 0.05) were inversely
correlated. After one year, correlations with borderline significance were calculated for
TBARS to New York Heart Association functional class (p 5 0.081) and inversely for LPO
to LVEF (p 5 0.083).
CONCLUSIONS Effective therapy in patients with IDC, such as immunoadsorption which improved cardiac
performance and clinical status, is associated with a reduction of oxidative stress. (J Am Coll
Cardiol 2001;38:178–83) © 2001 by the American College of Cardiology
The benefit of immunoglobulin adsorption (immunoad-
sorption) for the elimination of cardiac-specific autoanti-
bodies in patients with dilated cardiomyopathy was recently
reported. Mu¨ller et al. (1) found that cardiac performance
and clinical status improved one year after a cycle of
See page 184
immunoadsorption, which was performed on five consecu-
tive days. Improved hemodynamics after immunoadsorp-
tion, which was combined with subsequent immunoglobu-
lin G (IgG) substitution, was demonstrated by Felix et al.
(2), who performed immunoadsorption in four courses, at
one-month intervals, until month 3.
However, heart failure is associated with increased oxi-
dative stress (3–9), the extent of which correlates positively
with the class of heart failure (6,7,9) and negatively with
cardiac performance (4). Therefore, oxidative stress is be-
lieved to be involved in the development and progression of
heart failure (10,11). Consequently, beneficial treatment,
such as immunoadsorption, which improves cardiac perfor-
mance and clinical status (1,2), could result in the reduction
of oxidative stress that might contribute to the therapy
benefit.
To test this hypothesis, which would substantiate a close
relationship between oxidative stress and heart failure, we
compared in a substudy to Mu¨ller et al. (1) the prestudy and
one-year levels of plasma markers for oxidative stress in
patients with idiopathic dilated cardiomyopathy (IDC)
treated with immunoadsorption according to Mu¨ller et al.
(1) versus conventionally treated patients.
METHODS
Patient characteristics. In the present study, we analyzed
plasma samples that were collected from patients with IDC
who were characterized by Mu¨ller et al. (1) with regard to
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the effects of immunoadsorption versus conventional treat-
ment on cardiac performance and clinical status.
From the 32 patients with IDC who finished the Mu¨ller
et al. study (1), we included 31 patients (mean age: 47.8 6
10.3 years; range: 21 to 61 years, men: 29; women: 2) in our
study. One patient was excluded owing to a hemolytic
prestudy sample. All patients were accepted as candidates
for heart transplantation and had New York Heart Associ-
ation (NYHA) functional class II or worse, left ventricular
ejection fraction (LVEF) ,0.29, left ventricular internal
diameter in diastole (LVIDd) .64 mm and evidence for
cardiac-specific autoantibodies indicated by the presence of
anti-beta1-adrenoceptor autoantibodies (anti-beta1A-AB).
There was no evidence of coronary artery disease or any
other cardiac disease. Exclusion criteria were atrial fibrilla-
tion, infectious diseases, alcohol-induced cardiomyopathy,
previous allergic reaction to sheep protein and signs of
malignancy. Sixteen patients (mean age 45.6 6 10.0 years;
range: 30 to 59 years; men: 14; women: 2) were treated with
immunoadsorption and 15 (mean age: 50.1 6 10.6 years;
range: 21 to 61 years; men: 15) were conventionally treated.
One year after immunoadsorption, the anti-beta1A-AB
level (prestudy level: 5.9 6 1.2 laboratory units) was reduced
in the treatment group by approximately 90%. This was
accompanied by a highly significant improvement (p ,
0.0001) of cardiac performance (LVEF: 22.1 6 3.3 vs.
37.8 6 8.2%; LVIDd: 74.4 6 7.3 vs. 63.8 6 6.2 mm; left
ventricular internal diameter in systole [LVIDs]: 66.0 6 6.3
vs. 55.6 6 6.2 mm) and clinical status (NYHA functional
class I/II/III/IV: 0/2/13/1 vs. 7/9/0/0). By comparison, no
significant changes of the controls in anti-beta1A-AB
(prestudy level: 4.8 6 1.0 laboratory units) or in cardiac
performance (LVEF: 24.1 6 3.0 vs. 25.2 6 5.9%; LVIDd:
75.5 6 5.3 vs. 73.7 6 7.4 mm; LVIDs: 67.0 6 5.4 vs.
65.1 6 8.4 mm) and clinical status (NYHA functional class
I/II/III/IV: 0/4/11/0 vs. 0/7/6/2) were seen after conven-
tional treatment.
Written, informed consent was obtained from all pa-
tients. The study protocol was approved by the Human
Ethics Committee of the Humboldt University of Berlin,
Germany.
Medical treatment. At baseline, medical treatment for
heart failure was standardized in that all patients were
administered maximal tolerated dosages of angiotensin-
converting enzyme (ACE) inhibitors, digitalis, diuretics and
oral anticoagulants. In addition, patients were treated with
the beta-blocker bisoprolol for the first time. Dosage ad-
justments were made to achieve a systolic blood pressure of
100 to 110 mm Hg and a heart rate of 60 to 80 beats/min
within three months. All patients received a daily supple-
ment of a moderate dose of vitamins, minerals and trace
elements (OrthoCorPlus; Orthomol, Langenfeld, Germany).
Extracorporeal immunoglobulin adsorption, measure-
ment of anti-beta1A-AB and echocardiographic evalua-
tion. For the immunoadsorption, which was performed
according to the established method of low-density lipopro-
tein (LDL) elimination, adsorption columns containing
polyclonal anti-human immunoglobulin antibodies pro-
duced in sheep (12) were used.
Immunoadsorption was performed on five consecutive
days, and serum IgG levels were monitored. To eliminate
anti-beta1A-AB with an acceptable risk of infection, im-
munoglobulin G (IgG) reduction to ,120 mg/dl was
planned.
For the measurement of anti-beta1A-AB, a bioassay
recently described by Wallukat et al. (13) was used.
Transthoracic echocardiography was performed accord-
ing to the guidelines of the American Society of Echocar-
diography (14). (For more details, see Mu¨ller et al. [1]).
Sampling and measurement. As markers for oxidative
stress, we determined the levels of thiobarbituric acid-
reactive substances (TBARS) (15), lipid peroxides (LPO)
(PerOx; Immundiagnostik, Bensheim, Germany) (16), anti-
oxidized low-density lipoprotein-autoantibodies (anti-
oxLDL-AB) (oLAb Elisa; Biomedica, Wien, Austria), thiol
groups (17) and vitamin E (18) in venous plasma samples
(anticoagulated with 14,300 U/l heparin) collected prior to
the study and after one year.
To avoid unspecific marker changes by in vitro oxidation,
especially relevant to TBARS, LPO and thiol groups, and
to guarantee high precision in the analytical procedures,
adequate conditions for sampling, storage and measurement
were ascertained in prestudy experiments. Using the find-
ings of these experiments, samples and aliquots were pre-
pared under a nitrogen atmosphere, immediately frozen and
stored in liquid nitrogen until measurement. Both the
prestudy and one-year sample of each subject of both groups
were handled identically and—for high precision—analyzed
in parallel.
Statistical analysis. Data are expressed as mean 6 SD. A
log-transformation was applied to stabilize the variance. A
two-way repeated-measures analysis of variance (ANOVA)
was used to test for effect of time, group and their interac-
tion followed by the Student t test for paired and unpaired
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ANOVA 5 analysis of variance
anti-beta1A-AB 5 anti-beta 1-adrenoceptor antibodies
anti-oxLDL-AB 5 anti-oxidized low-density
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IDC 5 idiopathic dilated cardiomyopathy
IgG 5 immunoglobulin G
LPO 5 lipid peroxides
LVEF 5 left ventricular ejection fraction
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data. Linear regression was performed using the SPSS
software package (SPSS Inc., Chicago, Illinois).
RESULTS
Oxidative stress in patients with IDC one year after
immunoglobulin adsorption. The prestudy and one-year
levels of indicators for oxidative stress were widely scattered
in both patient groups, as shown by their SD (Fig. 1).
However, there were no significant group-specific differ-
ences prior to the study. Two-way ANOVA for analysis of
the overall effect of group allocation and repeated measures
on the markers for oxidative stress revealed significant time
effects but no interaction effects for TBARS (p 5 0.0001
[time effect p value] p 5 0.99 [interaction effect p value]),
thiol groups (p 5 0.001; p 5 0.1) and vitamin E (p 5 0.001;
p 5 0.43). In contrast, no time effects but a trend to
interaction was found for LPO (p 5 0.14; p 5 0.08) and
anti-oxLDL-AB (p 5 0.89; p 5 0.09).
In addition to highly significantly reduced anti-
beta1A-AB and improved cardiac performance and NYHA
functional class in the patients who underwent immunoad-
sorption, as demonstrated by Mu¨ller et al. (1), a significant
lowering was observed in these patients over the study
period by 1.24 6 0.5 mmol/l for TBARS (9.38 6 2.48 vs.
8.14 6 2.50 mmol/l; p 5 0.026), by 110.6 6 44.5 mmol/l
for LPO (268.6 6 186.1 vs. 157.9 6 71.7 mmol/l; p 5
0.026), and by 53.2 6 24.0 U/l for anti-oxLDL-AB
(323.1 6 221.4 vs. 269.9 6 153.1 U/l, p 5 0.044). In
contrast, TBARS decreased only by 0.87 6 0.6 mmol/l
(9.19 6 3.36 vs. 8.33 6 2.49 mmol/l, p 5 0.165) in the
controls. Both LPO (265.4 6 198.9 vs. 321.4 6 272.5
mmol/l, p 5 0.364) and anti-oxLDL-AB (200.4 6 78.7 vs.
222.6 6 97.3 U/l; p 5 0.334) increased by 56.0 6 59.6
mmol/l and 22.2 6 22.6 U/l, respectively, in the controls.
However, these changes were insignificant.
For the thiol groups, there was only an insignificant
change of 20.8 6 12.4 mmol/l (341.1 6 94.4 vs. 320.3 6
105.1 mmol/l; p 5 0.140) in the immunoadsorption group,
but thiols decreased significantly in the controls by 53.2 6
12.9 mmol/l (386.1 6 129.0 vs. 332.9 6 147.4 mmol/l, p 5
0.001). Vitamin E increased significantly over the study
period in the treated group by 20.56 6 2.9 mmol/l (34.44 6
Figure 1. Prestudy (black columns) and one-year levels (white columns) of plasma markers for oxidative stress in patients with idiopathic dilated
cardiomyopathy conventionally treated (nontreated, n 5 15) and treated with immunoglobulin adsorption (treated, n 5 16). Prestudy level versus one-year
level: 1p # 0.05; 11p # 0.001; nontreated versus treated: #p # 0.1. (A) Thiobarbituric acid-reactive substances (TBARS); (B) lipid peroxides (LPO); (C)
anti-oxidized low-density lipoprotein-autoantibodies (anti-oxLDL-AB); (D) thiol groups; (E) vitamin E (Vit. E).
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18.64 vs. 55.0 6 27.56 mmol/l, p 5 0.001) as well as in the
control group by 12.75 6 5.2 mmol/l (22.85 6 18.23 vs.
35.60 6 34.42 mmol/l, p 5 0.031) with a trend for stronger
accumulation in the immunoadsorption group (p 5 0.09).
Oxidative stress versus NYHA functional class and car-
diac performance. Prior to the study, a significant inverse
correlation of anti-oxLDL-AB to LVEF was calculated for
the complete population of patients (Fig. 2A). After one
year (Fig. 2B, C) the best correlations were found for
TBARS to NYHA functional class and inversely for LPO
to LVEF. Additionally, the anti-oxLDL-AB changes over
the study period correlated inversely to LVEF and directly
to LVIDs changes.
DISCUSSION
To our knowledge for the first time in humans, we dem-
onstrated that improvement of cardiac performance and
clinical status in heart failure, such as shown after immu-
noadsorption (1), is in parallel associated with a reduction of
oxidative stress.
This was demonstrated by measurement of markers
adaptable to clinical chemistry for analysis of oxidative stress
in human plasma (19) such as TBARS, LPO, and anti-
oxLDL-AB as indicators for lipid peroxidation; thiol
groups, for which a decrease signals thiol oxidation; and
vitamin E, an important nonenzymatic plasma antioxidant
for which a decrease indicates consumption due to oxidative
stress.
Oxidative stress in patients with IDC one year after
immunoglobulin adsorption. Decreased oxidative stress
one year after immunoadsorption was indicated by a low-
ering of TBARS, LPO and anti-oxLDL-AB, which was
not seen in the conventionally treated patients. With respect
to anti-oxLDL-AB, immunoadsorption is not antigen se-
lective and could—in addition to anti-beta1A-AB—
eliminate other IgG class antibodies such as anti-oxLDL-
Figure 2. Relationships between markers of oxidative stress and clinical status and cardiac performance in the complete population of patients
conventionally treated (solid diamonds) and those treated with immunoglobulin adsorption (open diamonds). (A) Anti-oxidized low density lipoprotein
autoantibodies (anti-oxLDL-AB) versus left ventricular ejection fraction (LVEF) prior to the study. (B) Thiobarbituric acid-reactive substances (TBARS)
versus New York Heart Association functional class one year after immunoadsorption. (C) Lipid peroxides (LPO) versus LVEF one year after
immunoadsorption. Prestudy to one-year change of anti-oxLDL-AB (d anti-oxLDL-AB) versus change of (D) LVEF (d LVEF), and (E) LVIDs (d
LVIDs).
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AB. Therefore, a delayed reincrease of anti-oxLDL-AB
could also explain the low anti-oxLDL level in the one-year
samples. Mu¨ller et al. (1) have speculated that antioxidant
supplementation could modulate the autoantibody rein-
crease. Although all patients received equal amounts of
OrthoCorPlus, which supplied vitamin E, there was a trend
to stronger accumulation of vitamin E in the plasma of the
patients who underwent immunoadsorption. We attribute
this effect to a lower consumption of vitamin E, due to
decreased oxidative stress in these patients. The significant
lowering of thiol groups over the study period, but only in
the controls, is a further indication of different levels of
oxidative stress in both groups.
Oxidative stress versus NYHA functional class and car-
diac performance. Close correlations for our patients be-
tween the intensity of oxidative stress and clinical status and
cardiac performance would substantiate the relationship
between oxidative stress and heart failure. Recently, such
correlations were demonstrated in studies that enrolled
patients with widespread data for cardiac performance and
clinical status (4,6,7,9), which favor regression analysis.
Regression analysis was limited by the small range of these
parameters in our patients, especially prior to the study, and
also by the relatively small number of patients in our study.
However, the correlations for oxidative stress, clinical status
and cardiac performance, demonstrated in Figure 2A–C,
supplement the findings of the other studies (4,6,7,9). At
present, it cannot be decided whether the correlations,
which were calculated for the prestudy to the one-year
changes of anti-oxLDL-AB and cardiac performance (Fig.
2D–E), support a close relationship between the intensity of
oxidative stress and the severity of heart failure. For that,
investigations must clarify the exact reasons—such as dis-
cussed above—for low anti-oxLDL-AB levels one year after
immunoadsorption.
Potential reasons for reduced oxidative stress after im-
munoglobulin adsorption. The reasons for reduced oxida-
tive stress in patients with IDC one year after immunoad-
sorption are unknown. Predisposing events of heart failure,
such as mechanical stress, ischemia, intoxication, viral myo-
carditis, reduced antioxidative defense due to malnutrition
and neurohumoral hyperstimulation, are thought to drive
myocardial oxidative stress (10,11), which can damage—via
thiol oxidation and lipid peroxidation—myocardial struc-
tures and functions (20,21) and in this way join the initial
pathophysiologic events and the development of heart
failure. Because of stimulated myocyte growth, apoptosis
and fibroblast proliferation during increased oxidative stress
(22), progression of heart failure could be favored.
Reduced mechanical stress, probably reduced inflamma-
tion after immunoadsorption together with the vitamin E
supplement, may minimize oxidative stress. Furthermore,
hyperstimulation of the myocardial beta-adrenergic path-
way, which is linked to heart failure (23), could increase the
oxygen radical generation by blockade of the electron
transport in the mitochondrial complex I (24). Therefore,
immunoadsorption of anti-beta1A-AB, believed to be in-
volved in the hyperstimulation of the myocardial beta-
adrenergic pathway, could reduce oxidative stress.
Study limitations. Decreases of plasma indicators for oxi-
dative stress do not inevitably reflect reduced oxidative stress
in the heart, which is favorable for an improvement of
function. Apart from the myocardium, perhaps poorly
perfused peripheral muscles and activated neutrophils may
be responsible for the oxidative stress found in plasma.
Future studies analyzing myocardial biopsies in parallel to
plasma seem to be warranted.
Conclusions. Improvement of clinical status and cardiac
performance in patients with ICD due to immunoadsorp-
tion is associated with a reduction of oxidative stress. This
could contribute to the benefit of immunoadsorption in
these patients.
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